QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
25.74
-1.34 (-4.97%)
Aug 14, 2025, 2:18 PM - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
Labs | 1.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Labs Growth | 3.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Point of Care | 694.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Point of Care Growth | -13.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Molecular Diagnostics | 24.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Molecular Diagnostics Growth | -0.39% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunohematology | 522.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunohematology Growth | 2.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Donor Screening | 115.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Donor Screening Growth | -45.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
North America Adjusted EBITDA | 892.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Adjusted EBITDA | 46.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Adjusted EBITDA | 130.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Adjusted EBITDA | 133.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Adjusted EBITDA | -659.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
North America | 1.62B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Growth | -8.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA | 335.80M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Growth | 4.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China | 325.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Growth | 3.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies | 502.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Growth | 5.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|